The efficacy and safety of collagenase Clostridium histolyticum (CCH) have been demonstrated in the treatment of men with Peyronie's disease (PD); however, the pivotal clinical trials excluded men with ventral penile curvature.
The study sought to evaluate outcomes of CCH treatment in men with ventral curvatures secondary to PD.
Men with PD treated with CCH were identified from a prospective database. Patients received up to 4 series of CCH injections using a progressively modified protocol over time. Results were compared between those with baseline ventral vs nonventral penile curvatures.
Changes in penile curvature, Peyronie's Disease Questionnaire scores, International Index of Erectile Function scores, nonstandardized assessments, and adverse events.
A total of 560 men with PD (85 ventral curvature, 475 nonventral curvature) were included in the analysis. Baseline median curvature was 60.0° (interquartile range, 48.8°-75.0°) in the ventral cohort and 65.0° (interquartile range, 45.0°-80.0°) in the nonventral cohort. Median change from baseline penile curvature was -25.0° in the ventral cohort vs -24.0° in the nonventral cohort (P = .08, between-group comparison), which corresponded to curvature reductions of 44.7% and 33.6%, respectively (P = .03). In the subset of patients who completed CCH treatment (ie, received 8 injections or discontinued early because of patient satisfaction with curvature reduction), median change from baseline was -35.0° in the ventral cohort vs -25.0° in the nonventral cohort (P < .05); median percent improvement was 48.3% and 37.5%, respectively (P = .11). Median change from baseline in Peyronie's Disease Questionnaire and International Index of Erectile Function domain scores and adverse events were similar between cohorts, with the exception of possibly higher hematoma rates in the nonventral group (50% vs 37%; P = .05). No urethral injuries were sustained in either cohort.
Data support the use of CCH for the treatment of ventral as well as nonventral penile curvatures in men with PD.
Study strengths are the inclusion of a general clinical population of men with PD, the prospective design, and the relatively large series of men with ventral curvature. Limitations include the single-center and observational nature of the study.
CCH was safe and effective in the treatment of both ventral and nonventral penile curvatures in men with PD.
The journal of sexual medicine. 2024 Jan 30 [Epub]
Henry Larson, Joshua Savage, Klint Brearton, Riley Warner, Matthew Ziegelmann, Tobias Kohler, Landon Trost
Brigham Young University, Department of Physiology and Developmental Biology, Provo, UT 84602, United States., Male Fertility and Peyronie's Clinic, Orem, UT 84057, United States., Mayo Clinic, Department of Urology, Rochester, MN 55905, United States.